PRINCETON, N.J., April 23 /PRNewswire/ -- Dr. Thomas M. Rossi, President and Chief Executive Officer of Agile Therapeutics, Inc., will report on the company's progress in developing a new generation of transdermal contraceptives at the BIO 2007 annual international conference on biotechnology. Agile is an early stage Women's Healthcare company, whose low estrogen dose, seven-day transdermal contraceptive patch is currently in phase 2 clinical development.
The BIO 2007 conference will be held at the Boston Convention and Exhibition Center in Boston, MA on May 6 - May 9th, 2007. Dr. Rossi is scheduled to present at 9:30 am in Room C.
Agile Therapeutics is privately held and supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.
About Agile Therapeutics
Agile Therapeutics, Inc. is a pharmaceutical product development company founded in 1997 based on developing novel pharmaceutical products utilizing its proprietary transdermal drug delivery technology. For more information, log on to www.agiletherapeutics.com.
Agile Therapeutics, Inc.CONTACT: Steve Ross, +1-908-507-7335
Web site: http://www.agiletherapeutics.com//
